SE
SERA.US Sera Prognostics Inc
- Market cap
- USD 79.5M
- P/E
- -
- P/B
- 1.46x
- ROE
- -65.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SERA.US undervalued?
Graham numberThe Graham number of Sera Prognostics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sera Prognostics Inc fundamental analysis
No fundamental analysis for Sera Prognostics Inc yet.
Sera Prognostics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sera Prognostics Inc
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services…
Full company profileSera Prognostics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sera Prognostics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 36.0K | 25.0K | 82.0K | 268K | 306K | 77.0K | 81.0K | 115K |
| Gross Profit | 18.0K | 14.0K | 45.0K | 75.0K | 96.0K | -5.00K | -83.0K | -89.3K |
| Operating Income | -16.6M | -18.0M | -35.4M | -45.7M | -39.8M | -36.6M | -36.5M | -37.7M |
| EBITDA | -13.6M | -17.1M | -33.6M | -43.4M | -35.3M | -32.0M | -31.0M | -33.3M |
| Net Income | -16.5M | -19.8M | -35.0M | -44.2M | -36.2M | -32.9M | -31.9M | -34.1M |
| EPS | -0.91 | -1.10 | -1.14 | -1.43 | -1.16 | -0.99 | -0.67 | -0.67 |
| Balance Sheet | ||||||||
| Total Assets | 23.3M | 14.8M | 147M | 116M | 95.4M | 72.6M | 102M | 80.0M |
| Total Liabilities | 12.3M | 11.9M | 8.47M | 17.4M | 25.3M | 24.8M | 26.5M | 27.5M |
| Shareholders' Equity | 11.0M | 2.94M | 139M | 98.9M | 70.2M | 47.8M | 75.4M | 52.4M |
| Cash & Short-term Investments | 21.4M | 13.5M | 105M | 82.7M | 49.1M | 46.2M | 39.2M | 44.1M |
| Total Debt | 9.32M | 8.57M | 128K | 2.83M | 1.86M | 840K | 2.34M | 3.27M |
| Cash Flow | ||||||||
| Operating Cash Flow | -19.3M | -16.9M | -31.6M | -34.6M | -27.2M | -14.2M | -25.6M | -29.8M |
| Capital Expenditure | 109K | 149K | 1.30M | 791K | 128K | 1.10M | 726K | 211K |
| Free Cash Flow | -19.4M | -17.0M | -32.9M | -35.4M | -27.3M | -15.3M | -26.3M | -30.1M |
| Ratios | ||||||||
| ROE | -150.8% | -675.1% | -25.3% | -44.7% | -51.7% | -68.8% | -42.3% | -65.1% |
| ROA | -71.0% | -134.1% | -23.8% | -38.0% | -38.0% | -45.3% | -31.3% | -42.7% |
| Net Profit Margin | -45,891.7% | -79,392.0% | -42,693.9% | -16,487.3% | -11,843.8% | -42,724.7% | -39,417.3% | -29,757.0% |
| Debt to Equity | 0.85x | 2.92x | 0.00x | 0.03x | 0.03x | 0.02x | 0.03x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sera Prognostics Inc dividends
Sera Prognostics Inc has not paid dividends in the last 7 fiscal years.
Who owns Sera Prognostics Inc
- Insiders 12.01%
- Institutions 56.81%
- Public & others 31.18%
- Shares outstanding 38.8M
- Free float 28.0M
Top funds holding SERA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| abrdn Healthcare Opportunities | 1.48M | 3.73% | +3.80% | Sep 2026 |
| abrdn Healthcare Investors | 1.47M | 3.69% | +2.66% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 887K | 2.23% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 161K | 0.40% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 99.3K | 0.25% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 50.6K | 0.13% | 0.00% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 49.8K | 0.13% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 47.3K | 0.12% | 0.00% | Sep 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 21.8K | 0.05% | -8.04% | Jun 2026 |
| Fidelity Nasdaq Composite Index | 19.0K | 0.05% | 0.00% | Aug 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 18.7K | 0.05% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 11.8K | 0.03% | 0.00% | Sep 2026 |
| GS Absolute Ret Trkr I Acc EUR Hdg | 11.4K | 0.03% | 0.00% | Aug 2026 |
| Vanguard U.S. Eq Idx £ Acc | 11.2K | 0.03% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 6.97K | 0.02% | 0.00% | Sep 2026 |
| Avantis US Small Cap Equity ETF | 5.40K | 0.01% | 0.00% | Oct 2026 |
| DFA U.S. Core Equity 1 I | 5.10K | 0.01% | 0.00% | Sep 2026 |
| Dimensional US Core Equity 1 ETF | 5.10K | 0.01% | 0.00% | Sep 2026 |
| Dimensional International Core Eq Acc | 3.63K | 0.01% | 0.00% | Sep 2026 |
| JNL/DFA US Small Cap A | 3.29K | 0.01% | 0.00% | Sep 2026 |
Top institutions holding SERA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Baker Bros Advisors LP | 5.50M | 13.83% | 0.00% | Jun 2026 |
| Whetstone Capital Advisors, LLC | 3.31M | 8.32% | 0.00% | Jun 2026 |
| Aberdeen Group PLC | 2.95M | 7.43% | +7.25% | Sep 2026 |
| Vivo Capital, LLC | 1.65M | 4.15% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.30M | 3.26% | +7.78% | Jun 2026 |
| CapTrust Financial Advisors | 536K | 1.35% | -0.19% | Jun 2026 |
| Geode Capital Management, LLC | 349K | 0.88% | -4.03% | Jun 2026 |
| BlackRock Inc | 221K | 0.56% | +12.88% | Jun 2026 |
| Awm Investment Company Inc | 207K | 0.52% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 171K | 0.43% | +0.74% | Jun 2026 |
| State Street Corp | 125K | 0.31% | 0.00% | Jun 2026 |
| Millennium Management LLC | 74.0K | 0.19% | -19.14% | Jun 2026 |
| Perigon Wealth Management, LLC | 72.7K | 0.18% | 0.00% | Jun 2026 |
| Northern Trust Corp | 68.6K | 0.17% | -28.94% | Jun 2026 |
| Bank of New York Mellon Corp | 60.9K | 0.15% | 0.00% | Jun 2026 |
| Bridgeway Capital Management, LLC | 55.7K | 0.14% | +21.88% | Jun 2026 |
| Requisite Capital Management, LLC | 55.6K | 0.14% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 51.0K | 0.13% | -51.46% | Jun 2026 |
| Qube Research & Technologies | 50.9K | 0.13% | +155.42% | Jun 2026 |
| Ballentine Finn & Company Inc | 49.7K | 0.12% | 0.00% | Jun 2026 |
Sera Prognostics Inc company profile
- Company name
- Sera Prognostics Inc
- Ticker
- SERA.US
- Exchange
- USA Stocks
- Listed since
- Jul 15, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 71
- Fiscal year end
- December
- Address
- 2749 East Parleys Way, Salt Lake City, UT, United States, 84109
- Phone
- 801 990 0520
- Website
- sera.com
About Sera Prognostics Inc
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Sera Prognostics Inc management
10- Ms. Zhenya Lindgardt M.B.A.President, CEO & Director · born 1974
- Dr. John J. Boniface Ph.D.Chief Scientific Officer · born 1962
- Dr. Gregory C. Critchfield M.D., M.S.Executive Director · born 1953
- Dr. Paul Kearney Ph.D.Chief Data Officer · born 1968
- Mr. Scott GleasonCFO & Treasurer · born 1979
- Mr. Robert G. HarrisonChief Information Officer · born 1966
- Ms. Jennifer ZibudaHead of Investor Relations
- Mr. Benjamin G. Jackson J.D.General Counsel & Corporate Secretary · born 1979
- Mr. Austin AertsAdvisor · born 1987
- Mr. Lee AndersonChief Commercial Officer